Loading…
Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial
Curcuma longa Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 fem...
Saved in:
| Published in: | Inflammopharmacology 2013-04, Vol.21 (2), p.129-136 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c443t-a0fe67f43501b2841520a5c3d98c13c540021a13be6d53b345156bf9ef73cec03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c443t-a0fe67f43501b2841520a5c3d98c13c540021a13be6d53b345156bf9ef73cec03 |
| container_end_page | 136 |
| container_issue | 2 |
| container_start_page | 129 |
| container_title | Inflammopharmacology |
| container_volume | 21 |
| creator | Madhu, K. Chanda, K. Saji, M. J. |
| description | Curcuma longa
Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 females) with primary knee OA received either placebo (400 mg twice daily) or NR-INF-02 (500 mg twice daily) or glucosamine sulphate (GS) (750 mg twice daily) alone or combination of NR-INF-02 and GS for 42 days. The efficacy was assessed during treatment period, on day 21 and day 42. The decrease in severity of pain symptom and function of affected knee as primary efficacy outcome measure was assessed by Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, respectively. The clinical examination of affected joint was measured by an orthopaedic specialist and using a Clinician Global Impression Change (CGIC) scale. The analysis of post-treatment scores following administration of NR-INF-02 using VAS, WOMAC, and CGIC at each clinical visit showed significant decrease (
p
|
| doi_str_mv | 10.1007/s10787-012-0163-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1427009464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1427009464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-a0fe67f43501b2841520a5c3d98c13c540021a13be6d53b345156bf9ef73cec03</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoMo7uzqD_AiOXpprXx2tzcZ_FhY8KCeQzpd2c3anYxJGhyv_nEzzOrRQ1FQ9dQL9RDygsFrBtC_KQz6oe-A8VZadOIR2TGlh05pGB6THYxcdVKP_IJclnIPALrX41NywQWXXPV8R35_sR7rkdo4U_Q-OOuONHm637LbVkuXFG8txZ81W1dpiLTeIa0ZbV0x1hN5sCH6baHfIyJNpWKyud7lUEN5Sy3NLTmt4RfO9LBYh1PqXIo1p2Vpo5qDXZ6RJ94uBZ8_9Cvy7cP7r_tP3c3nj9f7dzedk1LUzoJH3XspFLCJD5IpDlY5MY-DY8IpCcCZZWJCPSsxCamai8mP6Hvh0IG4Iq_OuYecfmxYqllDcbgsNmLaimGS9wCj1LKh7Iy6nErJ6M0hh9Xmo2FgTu7N2b1p7s3JvRHt5uVD_DatOP-7-Cu7AfwMlLaKt5jNfdpybC__J_UPcJKQqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1427009464</pqid></control><display><type>article</type><title>Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial</title><source>Springer Nature</source><creator>Madhu, K. ; Chanda, K. ; Saji, M. J.</creator><creatorcontrib>Madhu, K. ; Chanda, K. ; Saji, M. J.</creatorcontrib><description>Curcuma longa
Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 females) with primary knee OA received either placebo (400 mg twice daily) or NR-INF-02 (500 mg twice daily) or glucosamine sulphate (GS) (750 mg twice daily) alone or combination of NR-INF-02 and GS for 42 days. The efficacy was assessed during treatment period, on day 21 and day 42. The decrease in severity of pain symptom and function of affected knee as primary efficacy outcome measure was assessed by Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, respectively. The clinical examination of affected joint was measured by an orthopaedic specialist and using a Clinician Global Impression Change (CGIC) scale. The analysis of post-treatment scores following administration of NR-INF-02 using VAS, WOMAC, and CGIC at each clinical visit showed significant decrease (
p
< 0.05) compared to placebo. NR-INF-02 treated group showed a significant (
p
< 0.01) decrease in use of rescue medication, along with clinical and subjective improvement compared to placebo. The tolerability and acceptability profile of NR-INF-02 was better during the trial period. The study demonstrates safety and efficacy of NR-INF-02 as a useful treatment option for patients with primary painful knee OA.</description><identifier>ISSN: 0925-4692</identifier><identifier>EISSN: 1568-5608</identifier><identifier>DOI: 10.1007/s10787-012-0163-3</identifier><identifier>PMID: 23242572</identifier><language>eng</language><publisher>Basel: SP Birkhäuser Verlag Basel</publisher><subject>Allergology ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Curcuma - chemistry ; Curcuma longa ; Dermatology ; Female ; Gastroenterology ; Glucosamine - therapeutic use ; Humans ; Immunology ; Knee Joint - drug effects ; Male ; Middle Aged ; Osteoarthritis, Knee - complications ; Osteoarthritis, Knee - drug therapy ; Pain - drug therapy ; Pain - etiology ; Pain Measurement - drug effects ; Pain Measurement - methods ; Pharmacology/Toxicology ; Plant Extracts - therapeutic use ; Research Article ; Rheumatology ; Severity of Illness Index ; Single-Blind Method ; Treatment Outcome</subject><ispartof>Inflammopharmacology, 2013-04, Vol.21 (2), p.129-136</ispartof><rights>Springer Basel 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-a0fe67f43501b2841520a5c3d98c13c540021a13be6d53b345156bf9ef73cec03</citedby><cites>FETCH-LOGICAL-c443t-a0fe67f43501b2841520a5c3d98c13c540021a13be6d53b345156bf9ef73cec03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23242572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Madhu, K.</creatorcontrib><creatorcontrib>Chanda, K.</creatorcontrib><creatorcontrib>Saji, M. J.</creatorcontrib><title>Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial</title><title>Inflammopharmacology</title><addtitle>Inflammopharmacol</addtitle><addtitle>Inflammopharmacology</addtitle><description>Curcuma longa
Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 females) with primary knee OA received either placebo (400 mg twice daily) or NR-INF-02 (500 mg twice daily) or glucosamine sulphate (GS) (750 mg twice daily) alone or combination of NR-INF-02 and GS for 42 days. The efficacy was assessed during treatment period, on day 21 and day 42. The decrease in severity of pain symptom and function of affected knee as primary efficacy outcome measure was assessed by Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, respectively. The clinical examination of affected joint was measured by an orthopaedic specialist and using a Clinician Global Impression Change (CGIC) scale. The analysis of post-treatment scores following administration of NR-INF-02 using VAS, WOMAC, and CGIC at each clinical visit showed significant decrease (
p
< 0.05) compared to placebo. NR-INF-02 treated group showed a significant (
p
< 0.01) decrease in use of rescue medication, along with clinical and subjective improvement compared to placebo. The tolerability and acceptability profile of NR-INF-02 was better during the trial period. The study demonstrates safety and efficacy of NR-INF-02 as a useful treatment option for patients with primary painful knee OA.</description><subject>Allergology</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Curcuma - chemistry</subject><subject>Curcuma longa</subject><subject>Dermatology</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Glucosamine - therapeutic use</subject><subject>Humans</subject><subject>Immunology</subject><subject>Knee Joint - drug effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Osteoarthritis, Knee - complications</subject><subject>Osteoarthritis, Knee - drug therapy</subject><subject>Pain - drug therapy</subject><subject>Pain - etiology</subject><subject>Pain Measurement - drug effects</subject><subject>Pain Measurement - methods</subject><subject>Pharmacology/Toxicology</subject><subject>Plant Extracts - therapeutic use</subject><subject>Research Article</subject><subject>Rheumatology</subject><subject>Severity of Illness Index</subject><subject>Single-Blind Method</subject><subject>Treatment Outcome</subject><issn>0925-4692</issn><issn>1568-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kE2LFDEQhoMo7uzqD_AiOXpprXx2tzcZ_FhY8KCeQzpd2c3anYxJGhyv_nEzzOrRQ1FQ9dQL9RDygsFrBtC_KQz6oe-A8VZadOIR2TGlh05pGB6THYxcdVKP_IJclnIPALrX41NywQWXXPV8R35_sR7rkdo4U_Q-OOuONHm637LbVkuXFG8txZ81W1dpiLTeIa0ZbV0x1hN5sCH6baHfIyJNpWKyud7lUEN5Sy3NLTmt4RfO9LBYh1PqXIo1p2Vpo5qDXZ6RJ94uBZ8_9Cvy7cP7r_tP3c3nj9f7dzedk1LUzoJH3XspFLCJD5IpDlY5MY-DY8IpCcCZZWJCPSsxCamai8mP6Hvh0IG4Iq_OuYecfmxYqllDcbgsNmLaimGS9wCj1LKh7Iy6nErJ6M0hh9Xmo2FgTu7N2b1p7s3JvRHt5uVD_DatOP-7-Cu7AfwMlLaKt5jNfdpybC__J_UPcJKQqw</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>Madhu, K.</creator><creator>Chanda, K.</creator><creator>Saji, M. J.</creator><general>SP Birkhäuser Verlag Basel</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20130401</creationdate><title>Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial</title><author>Madhu, K. ; Chanda, K. ; Saji, M. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-a0fe67f43501b2841520a5c3d98c13c540021a13be6d53b345156bf9ef73cec03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Allergology</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Curcuma - chemistry</topic><topic>Curcuma longa</topic><topic>Dermatology</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Glucosamine - therapeutic use</topic><topic>Humans</topic><topic>Immunology</topic><topic>Knee Joint - drug effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Osteoarthritis, Knee - complications</topic><topic>Osteoarthritis, Knee - drug therapy</topic><topic>Pain - drug therapy</topic><topic>Pain - etiology</topic><topic>Pain Measurement - drug effects</topic><topic>Pain Measurement - methods</topic><topic>Pharmacology/Toxicology</topic><topic>Plant Extracts - therapeutic use</topic><topic>Research Article</topic><topic>Rheumatology</topic><topic>Severity of Illness Index</topic><topic>Single-Blind Method</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Madhu, K.</creatorcontrib><creatorcontrib>Chanda, K.</creatorcontrib><creatorcontrib>Saji, M. J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Inflammopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Madhu, K.</au><au>Chanda, K.</au><au>Saji, M. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial</atitle><jtitle>Inflammopharmacology</jtitle><stitle>Inflammopharmacol</stitle><addtitle>Inflammopharmacology</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>21</volume><issue>2</issue><spage>129</spage><epage>136</epage><pages>129-136</pages><issn>0925-4692</issn><eissn>1568-5608</eissn><abstract>Curcuma longa
Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 females) with primary knee OA received either placebo (400 mg twice daily) or NR-INF-02 (500 mg twice daily) or glucosamine sulphate (GS) (750 mg twice daily) alone or combination of NR-INF-02 and GS for 42 days. The efficacy was assessed during treatment period, on day 21 and day 42. The decrease in severity of pain symptom and function of affected knee as primary efficacy outcome measure was assessed by Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, respectively. The clinical examination of affected joint was measured by an orthopaedic specialist and using a Clinician Global Impression Change (CGIC) scale. The analysis of post-treatment scores following administration of NR-INF-02 using VAS, WOMAC, and CGIC at each clinical visit showed significant decrease (
p
< 0.05) compared to placebo. NR-INF-02 treated group showed a significant (
p
< 0.01) decrease in use of rescue medication, along with clinical and subjective improvement compared to placebo. The tolerability and acceptability profile of NR-INF-02 was better during the trial period. The study demonstrates safety and efficacy of NR-INF-02 as a useful treatment option for patients with primary painful knee OA.</abstract><cop>Basel</cop><pub>SP Birkhäuser Verlag Basel</pub><pmid>23242572</pmid><doi>10.1007/s10787-012-0163-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-4692 |
| ispartof | Inflammopharmacology, 2013-04, Vol.21 (2), p.129-136 |
| issn | 0925-4692 1568-5608 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1427009464 |
| source | Springer Nature |
| subjects | Allergology Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Biomedical and Life Sciences Biomedicine Curcuma - chemistry Curcuma longa Dermatology Female Gastroenterology Glucosamine - therapeutic use Humans Immunology Knee Joint - drug effects Male Middle Aged Osteoarthritis, Knee - complications Osteoarthritis, Knee - drug therapy Pain - drug therapy Pain - etiology Pain Measurement - drug effects Pain Measurement - methods Pharmacology/Toxicology Plant Extracts - therapeutic use Research Article Rheumatology Severity of Illness Index Single-Blind Method Treatment Outcome |
| title | Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T01%3A47%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20Curcuma%20longa%20extract%20in%20the%20treatment%20of%20painful%20knee%20osteoarthritis:%20a%20randomized%20placebo-controlled%20trial&rft.jtitle=Inflammopharmacology&rft.au=Madhu,%20K.&rft.date=2013-04-01&rft.volume=21&rft.issue=2&rft.spage=129&rft.epage=136&rft.pages=129-136&rft.issn=0925-4692&rft.eissn=1568-5608&rft_id=info:doi/10.1007/s10787-012-0163-3&rft_dat=%3Cproquest_cross%3E1427009464%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c443t-a0fe67f43501b2841520a5c3d98c13c540021a13be6d53b345156bf9ef73cec03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1427009464&rft_id=info:pmid/23242572&rfr_iscdi=true |